Sesen Bio Gets Unfavorable FDA Decision
August 13 2021 - 3:14PM
Dow Jones News
By Josh Beckerman
Sesen Bio Inc. said it is "deeply disappointed" after it
received a Complete Response Letter from the U.S. Food and Drug
Administration regarding its Biologics License Application for
Vicineum.
The company's shares were recently halted.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 13, 2021 15:11 ET (19:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024